魚躍醫療(002223.SZ):募投項目結項及終止 剩餘募集資金永久補充流動資金
格隆匯12月11日丨魚躍醫療(002223.SZ)公佈,為提高募集資金的使用效率,維護股東利益,公司擬對募投項目“丹陽醫療器械生產基地項目(二期)”進行結項,擬對“中優醫藥丹陽基地設備及配套投資項目”、“上手金鐘手術器械項目“、”上衞中亞醫用敷料項目“終止投入。
項目終止後剩餘募集資金及理財收益和利息收入41,391.89萬元(含利息收入等扣除銀行手續費的淨額,實際金額以資金轉出當日專户金額為準)將全部用於永久補充流動資金,能提升募集資金的使用效率、降低財務費用、提高資金使用效益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.